Systemic administration of a novel immune-stimulatory pseudovirion suppresses lung metastatic melanoma by regionally enhancing IFN-γ production

Clinical Cancer Research

Volumn 19, Issue 3, 2013, Pages 668-679

  Saga, Kotaro ^a   Tamai, Katsuto ^a   Yamazaki, Takehiko ^a   Kaneda, Yasufumi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; HEMAGGLUTININ; HN PROTEIN; HYBRID PROTEIN; IMMUNOGLOBULIN G; INTERLEUKIN 12; INTERLEUKIN 12 CONJUGATED HEMAGGLUTINATING VIRUS OF JAPAN ENVELOPE; ONCOLYTIC VIRUS; UNCLASSIFIED DRUG; VIRAL F PROTEIN; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG EFFICACY; ENZYME ACTIVITY; ERADICATION THERAPY; FEMALE; GENE CONSTRUCT; GENE TRANSFER; HEMAGGLUTINATING VIRUS OF JAPAN ENVELOPE; HEMAGGLUTINATION; LUNG METASTASIS; MELANOMA; METASTASIS POTENTIAL; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SENDAI VIRUS; SPLEEN CELL; VIRUS ENVELOPE; VIRUS EXPRESSION; VIRUS PARTICLE;

ANIMALS; CELL LINE; CRICETINAE; DISEASE MODELS, ANIMAL; FEMALE; HAPLORHINI; IMMUNOGLOBULIN FC FRAGMENTS; INJECTIONS, INTRALESIONAL; INTERFERON-GAMMA; INTERLEUKIN-12; LUNG NEOPLASMS; MELANOMA; MICE; SENDAI VIRUS; VIRAL FUSION PROTEINS; VIRION;

EID: 84873349192     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-1947     Document Type: Article

References (50)

1. Vignali DAA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev Immunol 2008;8:523-32.
2. Burch PA, Croghan GA, Gastineau DA, Jones LA, Kaur JS, Kylstra JW, et al. Immunotherapy (APC8015, Provenge®) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a phase 2 trial. Prostate 2004;60: 197-204.
3. Cheever MA, Higano CS. PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin Cancer Res 2011;17:3520-6.
4. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumabin patients with metastatic melanoma. N Engl J Med 2010;363:711-23.
5. Prieto PA, Yang JC, Sherry RM, Hughes MS, Kammula US, White DE, et al. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res 2012;18: 2039-47.
6. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54.
7. Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 2008;26:5233-9.
8. Kirkwood JM, Tarhini AA, Panelli MC, Moschos SJ, Zarour HM, Butterfield LH, et al. Next generation of immunotherapy for melanoma. J Clin Oncol 2008;26:3445-55.
9. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 2011;480:480-9.
10. Lamb RA, Kolakofsky D. Paramyxoviridae: the viruses and their replicaiton. Fields Virol 2001:1305-40.
11. Curran J, Kolakofsky D. Replication of paramyxoviruses. Adv Virus Res 1999;54:403-22.
12. Kurooka M, Kaneda Y. Inactivated Sendai virus particles eradicate tumors by inducing immune responses through blocking regulatory T cells. Cancer Res 2007;67:227-36.
13. Fujihara A, Kurooka M, Miki T, Kaneda Y. Intratumoral injection of inactivated Sendai virus particles elicits strong antitumor activity by enhancing local CXCL10 expression and systemic NK cell activation. Cancer Immunol Immunother 2008;57:73-84.
14. + T cell-mediated suppression by dendritic cells. Science 2003; 299:1033-6.
15. Lal G, Zhang N, Van Der Touw W, Ding Y, Ju W, Bottinger EP, et al. Epigenetic regulation of Foxp3 expression in regulatory T cells by DNA methylation. J Immunol 2009;182:259-73.
16. Benveniste EN. Cytokine actions in the central nervous system. Cytokine Growth Factor Rev 1998;9:259-75.
17. Tannenbaum CS, Tubbs R, Armstrong D, Finke JH, Bukowski RM, Hamilton TA. The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor. J Immunol 1998;161:927-32.
18. Bukowski RM, Rayman P, Molto L, Tannenbaum CS, Olencki T, Peereboom D, et al. Interferon-γ and CXC chemokine induction by interleukin 12 in renal cell carcinoma. Clin Cancer Res 1999;5:2780-9.
19. Seliger B, Hammers S, Höhne A, Zeidler R, Knuth A, Gerharz CD, et al. IFN-gamma-mediated coordinated transcriptional regulation of the human TAP-1 and LMP-2 genes in human renal cell carcinoma. Clin Cancer Res 1997;3:573-8.
20. Weber JS, Rosenberg SA. Modulation of murine tumor major histocompatibility antigens by cytokines in vivo and in vitro. Cancer Res 1988;48:5818-24.
21. Nakajima C, Uekusa Y, Iwasaki M, Yamaguchi N, Mukai T, Gao P, et al. A role of interferon-γ (IFN-4gM) in tumor immunity T cells with the capacity to reject tumor cells are generated but fail to migrate to tumor sites in IFN-γ-deficient mice. Cancer Res 2001;61:3399-405.
22. Pujade-Lauraine E, Guastalla JP, Colombo N, Devillier P, François E, Fumoleau P, et al. Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy. J Clin Oncol 1996;14:343-50.
23. Windbichler GH, Hausmaninger H, Stummvoll W, Graf AH, Kainz C, Lahodny J, et al. Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial. Br J Cancer 2000;82:1138-44.
24. Giannopoulos A, Constantinides C, Fokaeas E, Stravodimos C, Giannopoulou M, Kyroudi A, et al. The immunomodulating effect of interferon-γ intravesical instillations in preventing bladder cancer recurrence. Clin Cancer Res 2003;9:5550-8.
25. Marth C, Windbichler GH, Hausmaninger H, Petru E, Estermann K, Pelzer A, et al. Interferon-gamma in combination with carboplatin and paclitaxel as a safe and effective first-line treatment option for advanced ovarian cancer: results of a phase I/II study. Int J Gynecol Cancer 2006;16:1522-8.
26. Colombo MP, Trinchieri G. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev 2002;13:155-68.
27. Watford WT, Moriguchi M, Morinobu A, O'Shea JJ. The biology of IL-12: coordinating innate and adaptive immune responses. Cytokine Growth Factor Rev 2003;14:361-8.
28. Lieschke GJ, Rao PK, Gately MK, Mulligan RC. Bioactive murine and human interleukin-12 fusion proteins which retain antitumor activity in vivo. Nat Biotechnol 1997;15:35-40.
29. Foss DL, Moody MD, Murphy KP Jr, Pazmany C, Zilliox MJ, Murtaugh MP. In vitro and in vivo bioactivity of single-chain interleukin-12. Scand J Immunol 1999;50:596-604.
30. Nastala CL, Edington HD, McKinney TG, Tahara H, Nalesnik MA, Brunda MJ, et al. Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J Immunol 1994;153:1697-706.
31. Atkins MB, Robertson MJ, Gordon M, Lotze MT, DeCoste M, DuBois JS, et al. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res 1997;3:409-17.
32. Leonard JP, Sherman ML, Fisher GL, Buchanan LJ, Larsen G, Atkins MB, et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood 1997;90:2541-8.
33. Tashiro M, McQueen NL, Seto JT. Determinants of organ tropism of Sendai virus. Front Biosci 1999;4:D642-45.
34. Nilsson B, Moks T, Jansson B, Abrahmsen L, Elmblad A, Holmgren E, et al. A synthetic IgG-binding domain based on staphylococcal protein A. Protein Eng 1987;1:107-13.
35. Kawachi M, Tamai K, Saga K, Yamazaki T, Fujita H, Shimbo T, et al. Development of tissue-targeting hemagglutinating virus of Japan envelope vector for successful delivery of therapeutic gene to mouse skin. Hum Gene Ther 2007;18:881-94.
36. Shimbo T, Kawachi M, Saga K, Fujita H, Yamazaki T, Tamai K, et al. Development of a transferrin receptor-targeting HVJ-E vector. Biochem Biophys Res Commun 2007;364:423-8.
37. Saga K, Tamai K, Kawachi M, Shimbo T, Fujita H, Yamazaki T, et al. Functional modification of Sendai virus by siRNA. J Biotechnol 2008; 133:386-94.
38. Lee J, Nakagiri T, Oto T, Harada M, Morii E, Shintani Y, et al. IL-6 amplifier, NF-κB-triggered positive feedback for IL-6 signaling, in grafts is involved in allogeneic rejection responses. J Immunol 2012; 189:1928-36.
39. Lopez CB, Moltedo B, Alexopoulou L, Bonifaz L, Flavell RA, Moran TM. TLR-independent induction of dendritic cell maturation and adaptive immunity by negative-strand RNA viruses. J Immunol 2004;173: 6882-9.
40. Suzuki H, Kurooka M, Hiroaki Y, Fujiyoshi Y, Kaneda Y. Sendai virus F glycoprotein induces IL-6 production in dendritic cells in a fusion-independent manner. FEBS Lett 2008;582:1325-9.
41. + T cells. J Exp Med 1997;185:461-70.
42. Frassanito MA, Cusmai A, Dammacco F. Deregulated cytokine network and defective Th1 immune response in multiple myeloma. Clin Exp Immunol 2001;125:190-7.
43. Portner A, Scroggs RA, Metzger DW. Distinct functions of antigenic sites of the HN glycoprotein of sendai virus. Virology 1987;158:61-8.
44. Brunda MJ, Luistro L, Warrier RR, Wright RB, Hubbard BR, Murphy M, et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 1993;178:1223-30.
45. Schmidt CS, Mescher MF. Peptide antigen priming of naive, but not memory, CD8 T cells requires a third signal that can be provided by IL-12. J Immunol 2002;168:5521-9.
46. + regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis. Blood 2008;111:715-22.
47. Morizono K, Bristol G, Xie Y, Kung SK-P, Chen ISY. Antibody-directed targeting of retroviral vectors via cell surface antigens. J Virol 2001;75:8016-20.
48. Henning P, Andersson KME, Frykholm K, Ali A, Magnusson MK, Nygren P-A, et al. Tumor cell targeted gene delivery by adenovirus 5 vectors carrying knobless fibers with antibody-binding domains. Gene Ther 2005;12:211-24.
49. Morizono K, Xie Y, Ringpis G-E, Johnson M, Nassanian H, Lee B, et al. Lentiviral vector retargeting to P-glycoprotein on metastatic melanoma through intravenous injection. Nat Med 2005;11:346-52.
50. Kaneda Y, Nakajima T, NishikawaT, Yamamoto S, Ikegami H, Suzuki N, et al. Hemagglutinating virus of Japan (HVJ) envelope vector as a versatile gene delivery system. Mol Ther 2002;6:219-26.